What are various Exocrine Pancreatic Insufficiency (EPI) Therapeutics available in market today?

 

Exocrine pancreatic insufficiency is a medical condition where a person has a functional insufficiency for some reason such as having too little insulin in his body, then the pancreas will be unable to secrete sufficient amounts of insulin. This means that there is not enough glucose in the blood to provide the body with energy. When the body cannot absorb glucose, cells will starve to death. This causes damage to the pancreas, liver, and other organs of the body until a dysfunctional condition develops into Pancreatitis, which is an inflammation of the abdominal wall, pancreas, liver, or other organs.

There are many Exocrine Pancreatic Insufficiency (EPI) Therapeutics available in the market. One such drug, methotrexate, is often used in conjunction with insulin therapy. The goal of treatment with drugs is to reduce blood sugar levels and increase insulin so that cells can properly absorb glucose, making the body function normally again. Such treatments may be useful in relieving symptoms of Exocrine Pancreatic Insufficiency when they are administered after surgery.

However, some drugs can raise the risk of Exocrine Pancreatic Insufficiency. One drug, varenicline, is given to reduce nausea in people with diabetes. When taken by diabetics, it can increase the risk of heart attacks, strokes, excessive weight gain, kidney failure, and even liver disease. Other drugs such as prednisone and other immune suppressants can also make Exocrine Pancreatic Insufficiency worse.

In addition to using pancreatic enzyme injections, other Exocrine Pancreatic Insufficiency (EPI) Therapeutics may be available in the future for treating Exocrine Pancreatic Insufficiency. For instance, immunosuppressant drugs have been shown to slow down the progression of diabetes, and doctors often use these drugs to treat patients with autoimmune disorders such as multiple sclerosis, Lupus, and rheumatoid arthritis.